LAPK teaching topics
Introduction and Review of Basic pharmacokinetics, related responses,
and Clinical Applications
- New Optical Illusions
Ref.:
- Related Slides (.pdf)
- Review of Basic Pharmacokinetics
Ref.:
- Introduction to basic pharmacokinetics, and individualization of drug therapy (.pdf)
- Goal-oriented, model-based drug regimens: Setting individualized
goals for each patient (.pdf)
- Evaluating Renal Function
Ref.:
- Estimation of creatinine clearance in patients with unstable renal function,
without a urine specimen. (.pdf)
- Related slides (.pdf)
- Bayes' Theorem and the MAP Bayesian Scenario of Planning,
Monitoring, and Adjusting drug dosage for patients
Ref.:
- Achieving concentration goals using parametric pharmacokinetic models -
a clinical review of the current unimodal gaussian bayesian approach (.pdf)
- Bayes' Theorem (.pdf)
- New types of Bayesian Parameter Updating (.pdf)
- Modeling diffusion into endocardial vegetations, and the
postantibiotic effect
Ref.:
- Linked pharmacodynamic models: Diffusion into endocardial vegetations,
postantibiotic effect, and bacterial growth and kill (.pdf)
- Related slides (.pdf)
- Modeling bacterial growth and kill
- Demo Vancomycin - Setting the initial goals. Planning the initial
regimen. - Dr. Paul Beringer
Ref.:
- Clinical Applications: Vancomycin (.pdf)
- Introduction to Population Modelling
Why model? For description? For action? For what purpose?
Linear regression, Weighted Nonlinear Least Squares
Optimal procedures for population modelling
First, determine the assay error pattern, to weight each data point properly
Second, use a parametric population model, get gamma, ranges
Third, use an NP population model, use gamma, ranges, get
the entire parameter distribution. Why?
Ref.:
- Population pharmacokinetic models: Parametric and nonparametric approaches (.pdf)
- Related slides (.pdf)
- Optimal Strategies for PK/PD Studies and for Patient Monitoring
Ref.:
- Related slides (.pdf)
- Multiple Model Dosage Design for maximally precise goal oriented,
model based drug dosage regimens
Ref.:
- Multiple Model (mm) Dosage design: Achieving target goals with maximum precision (.pdf)
- Related slides (.pdf)
- Interacting Multiple Model Sequential Bayesian posterior joint parameter densities
to detect changing parameter values during the period of data analysis (.pdf)
- Maximum Entropy Methods for Creating Discrete Joint Densities for
Multiple Model Dosage Design - Dr. Mark Milman
Ref.:
- Related slides (.pdf)
Intermediate and Advanced Population Modeling
- Development of a Pharmacokinetic Model of Ciprofloxacin
in Adult CF Patients - Dr. Paul Beringer
Ref.:
- PK/PD of Ciprofloxacin in Patients with Cystic Fibrosis (.pdf)
- Determining the Assay Error Pattern: the First Step in Population
Modeling and TDM
Ref.:
- Fitting drug concentration data according to its credibility:
Determining the assay error pattern (.pdf)
- Related slides (.pdf)
- Bioavailability Studies
Ref.:
- Related slides (.pdf)
- Population PK/PD modeling
Ref.:
- POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC MODELING (.pdf)
- New advances in nonparametric pk/pd population modeling (.pdf)
- Adaptive grid NP models (.pdf)
- Population PK/PD modeling on the web (.pdf)
- A unified parametric/nonparametric approach to population PK/PD modeling (.pdf)
- Comparative Performance in analysing a clinical data set and two monte carlo simulation studies (.pdf)
- Optimal Drug dosage
Ref.:
- Multiple model dosage design (.pdf)
- Clinical Applications
Ref.:
- OPTIMIZING INDIVIDUALIZED DOSAGE REGIMENS OF POTENTIALLY TOXIC DRUGS (.pdf)
- Reduced transplant mortality (.pdf)
- A hemodynamic database (.pdf)
- Stochastic analysis (.pdf)
- Parametric and Nonparametric Population Methods (Preprint in Clinical Pharmacokinetics, 45:365-383, 2006)
Ref.:
- Their Comparative Performance in Analysing a Clinical Data Set and Two Monte Carlo Simulation Studies (.pdf)